SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.
| Website | http://www.sillajen.com |
| Employees | 30 (16 on RocketReach) |
| Founded | 2003 |
| Address | 450 Sansome St, San Francisco, California 94111, US |
| Industry | Biotechnology Research |
Looking for a particular SillaJen employee's phone or email?
SillaJen Questions
Sangkeun Park is the CEO, SillaJen Inc. and SillaJen Biotherapeutics (US) of SillaJen.
16 people are employed at SillaJen.
SillaJen is based in San Francisco, California.
Top SillaJen Employees
-
Seunghyun
Chief Medical Officer at SillaJen
San Diego, CA, US -
Jeong Moses
CTO, Head of CMC at SillaJen
South Korea -
Su Lee
Medical Director at SillaJen
San Diego, CA, US2 -
Zenny Astillo
Senior Manager, Corporate Accounting and Finance at SillaJen
California, United States21 -
2
-
Hyosun Song
Senior Safety Manager at SillaJen
South Korea1
